Evidence map›Paper›PMID 39694875›Full record

Observational studyEuropean journal of heart failure2025

Observational study for multiparametric assessment of cardiac congestion in outpatient worsening heart failure (EVOLUTION).

Gad Cotter, Beth Davison, Philip Janiak, Christopher Edwards, Maria Novosadova, Koji Takagi, Marie-Laure Ozoux, Francesca Lawson, Hamlet Hayrapetyan, Hamayak Sisakian and 6 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gad CotterUniversité Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France.
Beth DavisonUniversité Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France.
Philip JaniakCorteria Pharmaceuticals, Paris, France.
Christopher EdwardsMomentum Research Inc, Durham, NC, USA.
Maria NovosadovaMomentum Research Inc, Durham, NC, USA.
Koji TakagiMomentum Research Inc, Durham, NC, USA.
Marie-Laure OzouxCorteria Pharmaceuticals, Paris, France.
Francesca LawsonCorteria Pharmaceuticals, Paris, France.
Hamlet HayrapetyanCardiology Center of Erebouni MC, Yerevan State Medical University, Yerevan, Armenia.
Hamayak SisakianClinic of General and Invasive Cardiology, University Hospital #1, Yerevan State Medical University, Yerevan, Armenia.
Victor R Ter-GrigoryanCardiology Clinic, Nairi Medical Center, Yerevan, Armenia.
Katell Peoc'hClinical Biochemistry Laboratory, Bichat Hospital, APHP, Paris, France.
Alexandre RaynorClinical Biochemistry Laboratory, Bichat Hospital, APHP, Paris, France.
Paul BruzeauClinical Biochemistry Laboratory, Bichat Hospital, APHP, Paris, France.
Alexis NguyenUniversité Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France.
Alexandre MebazaaUniversité Paris Cité, INSERM UMR-S 942 (MASCOT), Paris, France.

Funding

Corteria Pharmaceuticals
6 · The paper itself

Abstract

aimsWe sought to characterize the clinical course of patients following worsening heart failure (WHF) treated in an outpatient setting and to identify factors associated with a poor response to standard of care with loop diuretics. METHODS AND

resultsBetween September 2022 and March 2023, 44 eligible patients (mean age 66.3 years, 84% male) with ejection fraction <50% and with WHF symptoms in the preceding week treated in an outpatient setting were enrolled. Patients were assessed weekly over 4 weeks following the WHF episode. At week 4, responses to fluid expansion and furosemide administration were assessed in 39 patients to unmask persistent subclinical congestion. Patients were on stable doses of guideline-directed medical therapy (GDMT) with a mean daily furosemide dose of 47.4 mg. Patient-reported and physician-assessed symptoms and quality of life improved over the 4 weeks. At 1 h following 1 L Ringer solution infused over 2 h, the median (interquartile range) urine volume and urine sodium excreted over 3 h were 300 (200.0-500.0) ml and 39.6 (12.4-63.0) mEq, respectively. Receiver-operating characteristic curves suggest that cystatin C >1.2 ng/ml, N-terminal pro-B-type natriuretic peptide (NT-proBNP) >1500 pg/ml, and high-sensitivity troponin T >20 pg/ml represent good predictors of non-response to a fluid challenge (diuresis, natriuresis, and rales) following an outpatient WHF, with having all three markers associated with the worst response.

conclusionPatients with high levels of troponin, or NT-proBNP, or cystatin C who develop WHF despite being treated with a loop diuretic, need novel therapies for WHF.

Indexed as

FurosemideHeart FailureOutpatientsStroke VolumeAgedDisease ProgressionFemaleHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsQuality of LifeSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Sodium Potassium Chloride Symporter InhibitorsHeart failureIntravascular fluid expansionOutpatient monitoringPrognostic factors

Identifiers

PMID39694875
PMCPMC11860726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.